The National Institute for Health and Care Excellence has for the first time recommended an oral treatment for preventing migraines. Rimegepant (also called Vydura and made by Pfizer) is recommended as an option for preventing episodic migraine in adults where at least three previous preventive treatments have failed. The final draft guidance recommends rimegepant for adults who have at least four migraine attacks per month but less than 15.
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.
Create a network to share documents, knowledge and best practice with your colleagues. Set up a network to keep in touch with other people in your organisation or with shared interest groups across organisational boundaries.
Networks can be open to all or available only to a closed group defined by the administrator.
Join or create a network here.
